Liu Yuan, Guo Dong, Yu Bin, Zeng Ting, Jiao Feng-Li, Bi Yan-Meng
College of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, China.
Department of Neurology, The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou, China.
J Ethnopharmacol. 2024 Apr 24;324:117754. doi: 10.1016/j.jep.2024.117754. Epub 2024 Jan 15.
Clinical research and basic scientific experiments have shown that modified Xiaoyaosan (MXYS) has antidepressant effects, whose system mechanism however has not been thoroughly characterized.
This research was aimed at evaluating the treatment effects of MXYS on chronic unpredictable mild stress (CUMS)-induced depressive mice and exploring underlying mechanisms.
Whether MXYS has effects on depression was investigated via the depressive behaviors of mice, electron microscopy, real-time quantitative polymerase chain reaction (RT-qPCR), Western blot analysis, immunofluorescence (IF) staining and the stereotaxic injection of adeno-associated viruses (AAVs). In addition, network pharmacology was applied to predict relevant molecular targets and possible mechanisms and perform further in vivo validation.
MXYS is effective in ameliorating the depression-like symptoms of CUMS mice. It can stimulate autophagosome formation, activate the expression of microtubule-associated protein 1 light chain 3 (LC3B), autophagy-related gene 5 (Atg5), Atg7 and neuron-specific nuclear protein (NeuN), and decrease the protein expression sequestosome 1 (SQSTM1/p62). The autophagy-upregulating effect of MXYS was weakened by silencing. The network pharmacology analysis revealed that mitogen-activated protein kinase 1 (MAPK1), MAPK3, serine/threonine-protein kinase (AKT1), proto-oncogene tyrosine-protein kinase (SRC), PI 3 kinase p85 alpha (PIK3R1), catenin (cadherin-associated protein) beta 1 (CTNNB1) and human thrombin activator 1 (HRAS) may be of importance to treat depression by MXYS. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that metabolic and autophagy pathways, pathways in cancer and MAPK, phosphoinositide 3-kinase (PI3K)-Akt and rhoptry-associated protein 1 (Rap1) signaling pathways are involved in the antidepressant effects of MXYS. As suggested by Western blot, the anti-depression mechanism of MXYS is possibly associated with the extracellular signal-regulated protein kinase (ERK)/P38 MAPK signaling pathway.
The findings indicate the possible antidepressant effects of MXYS on CUMS mice via triggering autophagy to alleviate neuronal apoptosis and prompting autophagy, which may involve the ERK/P38 MAPK signaling pathway.
临床研究和基础科学实验表明,加味逍遥散(MXYS)具有抗抑郁作用,但其系统机制尚未完全明确。
本研究旨在评估MXYS对慢性不可预测轻度应激(CUMS)诱导的抑郁小鼠的治疗效果,并探索其潜在机制。
通过小鼠的抑郁行为、电子显微镜、实时定量聚合酶链反应(RT-qPCR)、蛋白质免疫印迹分析、免疫荧光(IF)染色以及腺相关病毒(AAV)的立体定向注射,研究MXYS是否对抑郁症有影响。此外,应用网络药理学预测相关分子靶点和可能的机制,并进行进一步的体内验证。
MXYS可有效改善CUMS小鼠的抑郁样症状。它能刺激自噬体形成,激活微管相关蛋白1轻链3(LC3B)、自噬相关基因5(Atg5)、Atg7和神经元特异性核蛋白(NeuN)的表达,并降低聚集体蛋白1(SQSTM1/p62)的蛋白表达。沉默后MXYS的自噬上调作用减弱。网络药理学分析显示,丝裂原活化蛋白激酶1(MAPK1)、MAPK3、丝氨酸/苏氨酸蛋白激酶(AKT1)、原癌基因酪氨酸蛋白激酶(SRC)、PI 3激酶p85α(PIK3R1)、连环蛋白(钙黏着蛋白相关蛋白)β1(CTNNB1)和人凝血酶激活剂1(HRAS)可能对MXYS治疗抑郁症具有重要意义。京都基因与基因组百科全书(KEGG)富集分析显示,代谢和自噬途径、癌症相关途径以及MAPK、磷酸肌醇3激酶(PI3K)-Akt和Ras相关蛋白1(Rap1)信号通路参与了MXYS的抗抑郁作用。蛋白质免疫印迹分析表明,MXYS的抗抑郁机制可能与细胞外信号调节蛋白激酶(ERK)/P38 MAPK信号通路有关。
研究结果表明,MXYS可能通过触发自噬以减轻神经元凋亡并促进自噬,从而对CUMS小鼠产生抗抑郁作用,这可能涉及ERK/P38 MAPK信号通路。